Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02198261 · ClinicalTrials.gov registry record
Minoxidil Response Testing in Males With Androgenetic Alopecia
A clinical trial of Androgenetic Alopecia, sponsored by Applied Biology.
- Completed
- Registry status
- 300
- Enrollment target
- 5
- Study locations
NCT02198261: Completed study of Androgenetic Alopecia, sponsored by Applied Biology.
NCT02198261 is a study of Androgenetic Alopecia that has completed, run by Applied Biology. The registered enrollment target is 300 participants, above the 146-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (105% higher). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02198261, a study of Androgenetic Alopecia, has completed, sponsored by Applied Biology.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
Topical minoxidil is the most common drug used for the treatment of AGA in men. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i.e., 30-40% re-grow hair. To observe significant improvement in hair growth, minoxidil is typically used twice daily for a period of at least 16 weeks. Due to the significant time commitment and low response rate, a diagnostic test to identify non-responders prior to initiating therapy would be advantageous. Minoxidil is converted in the scalp to its active form, minoxidil sulfate, by the sulfotransferase enzyme SULT1A1. The enzyme expression is variable among individuals. We have demonstrated in two prior feasibility studies that the SULT1A1 enzyme activity in plucked hair follicles correlates with minoxidil response in the treatment of AGA and thus can server as a predictive biomarker. Consequently, we developed a minoxidil response in-vitro diagnostic kit intended to identify non-responders prior to initiating therapy with 5% topical minoxidil foam. The primary purpose of this study is to evaluate the clinical validity of the minoxidil response in-vitro diagnostic kit.
Conditions Studied
Interventions
- DRUG 5% minoxidil topical foam
Study Locations (5)
Other
- Sinclair Dermatology - East Melbourne
- LTM Medical College & Hospital - Mumbai
- Istituto Medico Tricologico/Studi Life Cronos - Florence
Arizona
- Physicians Hair Institute - Tucson
Tennessee
- Tennessee Clinical Research Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-10 |
What the finished NCT02198261 record still lists
NCT02198261 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 146-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (105% higher).
The record links to 1 condition, with Androgenetic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which 5% minoxidil topical foam is the first listed.
NCT02198261 lists 5 locations in 3 states (Other, Arizona, Tennessee).
Frequently Asked Questions
What is clinical trial NCT02198261 about?
NCT02198261 is a clinical study titled "Minoxidil Response Testing in Males With Androgenetic Alopecia". Topical minoxidil is the most common drug used for the treatment of AGA in men. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i.e., 30-40% re-grow hair. To observe significant improvement in hair growth, minoxidil is typically u...
What is the current status of trial NCT02198261?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2014-07. Estimated completion is 2018-10.
What conditions does trial NCT02198261 study?
This clinical trial studies the following conditions: Androgenetic Alopecia.
What interventions are being tested in trial NCT02198261?
The interventions under investigation include: 5% minoxidil topical foam (DRUG).
Who is sponsoring clinical trial NCT02198261?
This trial is sponsored by Applied Biology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02198261 being conducted?
This trial has 5 study locations across Arizona, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02198261's enrollment target sits among peer trials
300 5th of 16 higher than 12 of 16 other Androgenetic Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Androgenetic Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
RECRUITING · Phase 3
-
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
RECRUITING · NA
-
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
RECRUITING · NA
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia